Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Revumenib |
Trade Name | Revuforj |
Synonyms | SNDX5613|SNDX 5613|SNDX-5613 |
Drug Descriptions |
Revuforj (revumenib) inhibits the interaction between Menin and KMT2A (MLL), potentially resulting in antitumor activity and decreased proliferation of tumor cells with KMT2A (MLL) rearrangements or NPM1 mutations (PMID: 36922593, PMID: 36922589). Revuforj (revumenib) is FDA-approved for use in adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia harboring KMT2A translocation (FDA.gov). |
DrugClasses | MEN1-KMT2A Inhibitor 8 |
CAS Registry Number | 2169919-21-3 |
NCIT ID | C165776 |